
You must be at least 21 years old to access this website.
Our Products are for research and/or investigative purposes and are not suitable for direct human consumption or consumers, nor are they intended for clinical or therapeutic use. The statements and products listed on this website are not intended to diagnose, treat, cure, or prevent any disease. As such, they have not been evaluated or approved by the Federal Food and Drug Administration (the “FDA”). We are not a compounding pharmacy or outsourcing facility as defined under either Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Your cart is empty
Add compounds to get started
Research Comparison
CJC-1295 and Tesamorelin are both GHRH analogs that act on the GHRH receptor, but they differ in modification and duration. CJC-1295 with DAC is engineered for a long, sustained half-life, while Tesamorelin uses a trans-3-hexenoic acid modification for stability.
| Attribute | CJC-1295 | Tesamorelin |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Modification | Drug Affinity Complex (DAC) | Trans-3-hexenoic acid |
| Half-life profile | Extended (days) | Stabilized (hours) |
| Research focus | Sustained GH-axis signaling | GH axis + visceral adipose models |
Both are GHRH analogs acting on the GHRH receptor, but they use different chemical modifications. CJC-1295 (DAC) is engineered for an extended half-life; Tesamorelin is stabilized for GH-axis and metabolic research.